INTRODUCTION
============

Pleural empyema (PE), also known as empyema thoracis and pyothorax, is pus or bacteria in the pleural space.^[@R1]^ Despite ever-advancing technology, PE remains endemic worldwide. PE may evolve into necrosis, fistula in the thorax, and sepsis; thus, it is also associated with high mortality. The mortality rate of patients with PE can be up to 20%,^[@R2],[@R3]^ even under strict therapeutic regimens. Moreover, the incidence of PE has increased worldwide in past years^[@R1],[@R3]--[@R5]^; a review article stated that the rate of pneumococcal pneumonia in adults with empyema increased from 7.6% (1996--2001) to 14.9% (2005--2011).^[@R6]^

Aortic aneurysm (AA), a pathological dilation of the aortic wall, is typically classified as resulting from atherosclerotic processes, inflammatory courses, aortic dissection, infection, trauma, or a congenital etiology.^[@R7]^ Confirmed risk factors of AA include smoking, hypertension, age, and hyperlipidemia.^[@R8],[@R9]^ The most common form of AA is abdominal AA (AAA). An American systematic review estimated that AAA affects up to 1.3% of women and up to 7.2% of men ages 50 years or older.^[@R10]^ AAA also accounts for more than 10,000 deaths per year in the United States.^[@R11]^

A form of AA, infectious aneurysm (IA), also known as mycotic aneurysm, consists of dilatations caused by devastation of the aortic wall by organisms. The mechanisms of underlying IA include bacteremic seeding of existing atherosclerotic plaque or damaged intima (most common), septic emboli of the aortic vasa vasorum, and contiguous infective focus extending to the aortic wall (rare).^[@R12]^ Diagnosing IA as early as possible is crucial because the natural course of untreated IA is fatal.^[@R12],[@R13]^ The factors predisposing arteries to IA are impaired immunity, infective endocarditis, congenital aortic anomalies, aortic trauma, and atherosclerosis.^[@R12],[@R14],[@R15]^ Old age, non-*Salmonella* infection, location of the IA, and with/without operation have been identified as determinants of IA mortality.^[@R12],[@R16],[@R17]^

PE has been reported to be associated with IA. Thoracic IA resulting in death has been suspected to be caused by bilateral encapsulation of PE.^[@R18]^ Sommer et al^[@R19]^ also described a septic rupture of the aorta in a patient with PE. Atherosclerosis and preexisting aneurysms precipitate IA; therefore, further large-scale investigation is warranted to elucidate the relationship between PE and all types of AA. Thus, we conducted this retrospective nationwide cohort study by using a health insurance database representative of the population of Taiwan. We hypothesized that PE is linked with an increased risk of AA.

MATERIALS AND METHODS
=====================

Data Source
-----------

The Taiwan National Health Insurance (NHI) program is a mandatory, single-payer health insurance system in which all residents are required to participate. The NHI program was initiated by the Taiwan Government in 1995 and covers more than 99% of the 23 million residents of Taiwan.^[@R20]^ The NHI Research Database (NHIRD) is a nationwide database of reimbursement claims data obtained from the NHI program and is maintained by the National Health Research Institutes (NHRI). The NHRI encrypts all patient identification numbers for the protection of privacy and provides researchers with anonymous numbers to link the relevant claims information such as patient sex, date of birth, medical claims and types of care, and medication prescriptions. For this cohort study, we used a subset of the NHIRD including files of inpatient claims and the Registry of Beneficiaries. Disease diagnosis was based on disease records according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH-104-REC2-115). The IRB also specifically waived the consent requirement.

Study Patients
--------------

Patients newly diagnosed with PE (ICD-9-CM codes 510, 510.0, 510.9) from 2000 to 2011 were identified from the inpatient claims data as a PE cohort. The date of the first admission for PE was used as the index date.

Patients diagnosed with AA (ICD-9-CM code 441) at the baseline, ages under 20 years, and with incomplete information on demographics were excluded. Four times as many control patients as PE patients were randomly selected from all NHI beneficiaries without PE, and the same exclusion criteria were applied. The non-PE cohort patients were frequency matched with the PE patients by age (in 5-year bands), sex, and the index year. All study patients were followed-up until they were diagnosed with AA, which was identified on the basis of hospitalization records. The follow-up period was the period from the index date to the date of AA diagnosis, withdrawal from the insurance system, death, or the end of 2011.

Comorbidities
-------------

The baseline comorbidities of diabetes (ICD-9-CM code 250), hypertension (ICD-9-CM codes 401--405), hyperlipidemia (ICD-9-CM code 272), chronic obstructive pulmonary disease (COPD) (ICD-9-CM codes 491, 492, 496), heart failure (ICD-9-CM code 428), coronary artery disease (CAD) (ICD-9-CM codes 410--414), stroke (ICD-9-CM codes 430--438), bacterial endocarditis (ICD-9-CM code 421), and rheumatic endocarditis (ICD-9-CM codes 391.1, 394.0--397.9) were identified according to diagnoses in the hospitalization records prior to the index date.

Statistical Analysis
--------------------

The baseline characteristics and comorbidities of the PE and non-PE cohorts were compared. Chi-squared and *t* tests were used to determine the differences in categorical and continuous variables, respectively, between the 2 cohorts. The AA cumulative incidence curves were estimated for both cohorts by using Kaplan--Meier analysis and a log-rank test. The overall, sex-, age-, comorbidity-, and follow-up-time-specific incidence density rates (per 1000 person-years) of AA were calculated for each cohort. Univariate and multivariate Cox proportional hazards regression analyses were used to assess the hazard ratio (HR) and 95% confidence interval (CI) of AA development associated with PE, compared with that of the non-PE cohort. The multivariate models were simultaneously adjusted for age, sex, and comorbidities of diabetes, hypertension, hyperlipidemia, COPD, heart failure, CAD, stroke, bacterial endocarditis, and rheumatic endocarditis, all of which showed a significant difference (Table [1](#T1){ref-type="table"}). Further data analysis was performed to evaluate the joint effect for AA between PE and AA-associated risk factors. We used SAS software (version 9.4 for Windows; SAS Institute Inc., Cary, NC) for all data analyses. A *P* value \< 0.05 was considered statistically significant.
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RESULTS
=======

This study consisted of 34,250 patients with PE and 137,000 patients without PE. Table [1](#T1){ref-type="table"} shows the characteristics of the study patients in the 2 cohorts; men (77.2%) and patients older than 65 years of age (49.0%) were predominant in both groups. The mean ages of the PE and non-PE cohorts were 62.5 ± 16.5 and 61.9 ± 16.6 years, respectively. Compared with the non-PE cohort, comorbidities were more prevalent in the PE cohort (*P* \< 0.001). The mean follow-up periods were 3.27 ± 3.25 years in the PE cohort and 5.36 ± 3.10 years in the non-PE cohort (*P* \< 0.001). The Kaplan--Meier analysis revealed that the cumulative incidence of AA was higher for the PE cohort than for the non-PE cohort (log-rank test, *P* \< 0.001; Figure [1](#F1){ref-type="fig"}).

![Cummulative incidence of aortic aneurysmin patients with pleural empyema and comparison patients.](medi-94-e2142-g002){#F1}

The overall incidence density rate of AA was 1.59-fold higher in the PE cohort than in the non-PE cohort (1.32 vs 0.83 per 1000 person-years), with an adjusted HR (aHR) of 1.69 (95% CI, 1.39--2.05) after controlling for age, sex, and comorbidities (diabetes, hypertension, hyperlipidemia, COPD, heart failure, CAD, stroke, bacterial endocarditis, and rheumatic endocarditis; Table [2](#T2){ref-type="table"}). Except for the patients ages ≥ 80 years, the patients with PE had a significantly higher risk of AA than the patients without PE did, stratified by sex (aHR = 2.22, 95% CI = 1.43--3.46 for women; aHR = 1.59, 95% CI = 1.28--1.97 for men), age group (aHR = 4.22, 95% CI = 2.24--7.95 for ≤49 years; aHR = 1.68, 95% CI = 1.08--2.63 for 50--64 years; aHR = 1.42, 95% CI = 1.06--1.89 for 65--79 years), and comorbidities (aHR = 2.01, 95% CI = 1.44--2.81 for comorbidities; aHR = 1.31, 95% CI = 1.03--1.65 for no comorbidities). The analysis stratified by follow-up duration revealed that the PE cohort had a higher risk than the non-PE cohort did during the 2 years of follow-up (aHR = 1.37, 95% CI = 1.04--1.80). PE patients with only bacterial endocarditis had the highest risk of AA (aHR = 32.7, 95% CI = 4.59--233.0), followed by those with only CAD (aHR = 2.04, 95% CI = 1.25--3.32), and those with only PE (aHR = 2.00, 95% CI = 1.43--2.79). Moreover, compared with the non-PE patients without these comorbidities, among patients with PE, those with 2 or more comorbidities were at a significantly increased risk of AA (aHR = 2.81, 95% CI = 2.17--3.63), followed by those with 1 comorbidity (aHR = 2.11, 95% CI = 1.49--2.98; Table [3](#T3){ref-type="table"}).
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DISCUSSION
==========

We hypothesized that PE is independently associated with subsequent AA, regardless of the antecedent comorbidities. To elucidate the relationship between AA risk and PE, in this study, the interference of sex, age, and comorbidities was reduced as much as possible by statistically adjusting for the risk of AA in the PE group.

We investigated the AA incidence rate in 34,250 patients with PE by analyzing claims data from the NHIRD. The PE group exhibited a significantly higher risk (HR = 1.69; 95% CI = 1.39--2.05) of AA compared with the non-PE group. Our data revealed that the PE patients exhibited a higher risk of developing AA regardless of sex, and age seemed to exert a reversed effect on the risk of developing AA. The overall incidence of AA was 59% higher in the PE than in the non-PE group. A significantly higher risk of PAD was noted after the 2nd year until the end of the follow-up period.

Several factors may be considered surrogates for AA to explain the relationship between PE and AA. First, in this study, the patients with PE were older and had a higher incidence of comorbidities compared with the non-PE patients (Table [1](#T1){ref-type="table"}). Patients with diabetes mellitus are not only at an increased risk of *Klebsiella pneumoniae*-related empyema^[@R21]^ but also have a greater risk of atherosclerosis. Moreover, age, hypertension, hyperlipidemia, and COPD are risk factors for AA^[@R8],[@R22]^; furthermore, patients with CAD or stroke have a higher risk of general atherosclerosis. In this study, the patients with these comorbidities tended to exhibit a greater risk of AA than did the patients without these comorbidities.

Second, IA is a form of AA; although considerably rare, an association between PE and IA has been proposed.^[@R18],[@R23]^ A case resulting in death indicated that bacterial extension of PE may cause fatal IA.^[@R18]^ Moreover, there are outcomes of researches support a link between IA and PE: Dénes et al^[@R24]^ stated that *Streptococcus pneumonia* infection intensifies atherosclerosis. Atherosclerosis is a crucial risk factor for aortic infection 15 and AA. Moreover, *S pneumonia* is a common pathogen of PE,^[@R6],[@R25]^ and it is also a pathogen of IA.^[@R26]--[@R29]^ Thus, patients with *S pneumonia* empyema may be at a higher risk of AA. *Mycoplasma pneumonia*, a possible pathogen of PE,^[@R30],[@R31]^ is suspected to be associated with the development of subsequent AA because of cross-reactivity of the human heat shock protein with the immune response to bacterial antibodies^[@R32]^ or because of increased adventitial inflammation, inhibition of TIMP-1 activity, and increased collagen degradation.^[@R33]^ Methicillin-resistant *Staphylococcus aureus* (MRSA), a severe cause of empyema, was reported to be associated with atherosclerosis^[@R34]^; thus, patients with MRSA-induced empyema may be at a higher risk of AA. There are 2 potential mechanisms of PE inducing IA. First, extension of a contiguous infection (PE) can lead to an IA, and has been described.^[@R35]--[@R38]^ The histological finding in a previous article even suggested that an IA of the thoracic aorta was caused by direct bacterial extension from PE.^[@R18]^ However, further investigations of the pathogenesis including signal transduction pathway and gene regulation are required. Second possible mechanism of PE inducing IA: bacteremic seeding of an atherosclerotic lesion, existing intimal injury, or preexisting aneurysm. PE with concomitant bacteremia is not a rare event.^[@R39],[@R40]^ It is also well-known that the intima is normally resistant to infection; however, bacteria can pass through the intima into deeper layers of the arterial wall when the intima is diseased. Then, after focal suppuration and perforation, an IA occurs. Moreover, the aorta is the common location affected by primarily bacteremic seeding, since it is the common site of atherosclerosis.

The strength of our study is that it is the first cohort study focusing on AA in PE patients, using consistent data collection and a large sample size for meaningful analyses. However, the study also had several limitations. First, despite adjustment for confounding factors, we may not have completely avoided the confounding effects of the preexisting comorbidities of AA, potentially resulting in an imprecise estimation of the relationship between PE and AA. Second, NHIRD diagnoses are documented using ICD-9-CM codes, and data on environmental risk factors influencing AA and PE, such as smoking^[@R1]^ and family history, could not be obtained. Third, the etiologic, anatomic, and pathologic characteristics of AA were unavailable in the NHIRD database. Thus, association of PE with different types of AA, in particular the IA or mycotic aneurysm, could not be analyzed. Finally, although the outcome of our research is consistent with the studies on the possible role of PE in increasing risk of AA, there is still a lack of experimental demonstration and biological plausibility. Further researches to unravel the pathogenesis between PE and AA are warranted.

In conclusion, patients with PE are linked with an increased risk of AA, regardless of preexisting comorbidities. AA in both infectious and noninfectious forms is life-threatening; therefore, we strongly suggest further investigation of expected possibility and frequency of AA may minimize its severe consequences.

Abbreviations: AA = aortic aneurysm, aHR = adjusted hazard ratio, BNHI = Bureau of National Health Insurance, CI = confidence interval, CVD = cardiovascular disease, HR = hazard ratio, IA = infectious aneurysm, ICD-9-CM = International Classification of Diseases 9th Revision Clinical Modification, IRB = Institutional Review Board, LHID 2000 = Longitudinal Health Insurance Database 2000, NHI = Taiwan National Health Insurance, NHIRD = National Health Insurance Research Database, PE = pleural empyema.

C-YW and T-WS were contributed equally to this work.

Conception and design: C-YW, T-WS, K-YH; administrative support: P-JK, S-YY, T-CS; collection and assembly of data: C-LL, C-HK; data analysis and interpretation: T-YC, C-LL, C-HK; manuscript writing: all authors; final approval of manuscript: all authors. C-YW and T-WS contributed equally to this work.

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002); China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project (BM104010092); NRPB Stroke Clinical Trial Consortium (MOST 103-2325-B-039-006); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan; and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.

The authors have no conflicts of interest to disclose.
